Combination targeted treatment produces lasting remissions in people with resistant aggressive B-cell lymphoma
Embargoed for Release
Wednesday, June 19, 2024
5:00 p.m. ET Contact: NCI Press Office
240-760-6600
NCIPressOfficers@nih.gov
NOTE: A virtual briefing is scheduled for Tuesday, June 18, 2024, at 1:00 p.m. ET. Details below.
Researchers at the National Institutes of Health (NIH) have developed a non-chemotherapy treatment regimen that is achieving full remissions for some people with aggressive B-cell lymphoma that has come back or is no longer responding to standard treatments. The five-drug combination targets multiple molecular pathways that diffuse large B-cell lymphoma (DLBCL) tumors use to survive.
In ...















